Us was the largest of Pharming Group N.V.’s 2 reported lines in fiscal 2025, at $311.67M — 97% of $319.77M.
| Products and services [axis] | FY 2018 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|
| Us | $200.08M | $221.20M | $246.60M | $311.67M | ||
| Europe | — | — | — | — | ||
| Europe & Row | $5.54M | $5.90M | $5.59M | $8.10M | ||
| Row | — | — | — | — | ||
| Total | $205.62M | $227.10M | $252.19M | $319.77M |
In fiscal 2025, which ended December 31, 2025, the 2 revenue lines Pharming Group N.V. reported in this breakdown added up to $319.77M. That is less than the $361.75M in its breakdown by revenue line, so these revenue lines do not account for all of its revenue that year. Us was the largest revenue line, at $311.67M or 97.5% of the total, followed by Europe & Row ($8.10M, 2.5%).
Compared with fiscal 2024, Europe & Row grew the fastest, rising 44.9% to $8.10M.
The table also keeps 2 revenue lines that Pharming Group N.V. no longer reports, so earlier years can still be read on their original basis; use "Show 2 discontinued" beneath the table to see them. This breakdown covers 6 fiscal years between 2018 and 2025, as reported in Pharming Group N.V.'s annual filings.
Ruconest was the largest of Pharming Group N.V.’s 2 reported lines in fiscal 2025, at $311.67M — 86% of $361.75M.
| Products And Services | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Ruconest | $200.08M | $221.20M | $246.60M | $311.67M | |
| Joenja | — | $17.89M | $40.50M | $50.07M | |
| Total | $200.08M | $239.09M | $287.10M | $361.75M |
In fiscal 2025, which ended December 31, 2025, the 2 revenue lines Pharming Group N.V. reported in this breakdown added up to $361.75M. That was up 26.0% from $287.10M in fiscal 2024. Ruconest was the largest revenue line, at $311.67M or 86.2% of the total, followed by Joenja ($50.07M, 13.8%).
Compared with fiscal 2024, Ruconest grew the fastest, rising 26.4% to $311.67M.
Joenja was first reported as a separate revenue line in fiscal 2023. This breakdown covers every fiscal year from 2021 to 2025, as reported in Pharming Group N.V.'s annual filings.
Pharming Group N.V. (PHAR) breaks its revenue down by revenue line. In fiscal 2025, its largest revenue line was Us, with $311.67M or 97.5% of the total, followed by Europe & Row at $8.10M (2.5%).
Us was Pharming Group N.V.'s largest revenue line in fiscal 2025, with $311.67M in revenue, 97.5% of the $319.77M reported across its 2 revenue lines.
Of the Pharming Group N.V. revenue lines reported in both fiscal 2024 and fiscal 2025, and making up at least 2% of the total, Europe & Row grew the fastest, rising 44.9% from $5.59M to $8.10M.
Every figure is taken from Pharming Group N.V.'s annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.
The breakdown by revenue line covers fiscal 2018 to 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.